Skip to the content
Altai Oncology - Softwarelogo darklogo light
  • Library
  • Articles
  • Patient Education
  • F.A.Q.
  • Contact Us
Altai Oncology - Softwarelogo darklogo light
Non-Small Cell Lung Cancer

New Reference: Encorafenib and Binimetinib in bRAF V600E Mutated NSCLC

Ulas D. Bayraktar, MD
2023-06-24
Non-Small Cell Lung Cancer

New Drug: Pralsetinib for non-small cell lung cancer with RET gene fusions

Ulas D. Bayraktar, MD
2023-06-07
Non-Small Cell Lung Cancer

New Indication: Adjuvant Pembrolizumab for NSCLC

Ulas D. Bayraktar, MD
2023-03-15
Non-Small Cell Lung Cancer

New Indication: Durvalumab with Tremelimumab in Metastatic NSCLC

Ulas D. Bayraktar, MD
2023-01-10
Non-Small Cell Lung Cancer

New Protocol: Cemiplimab with Chemotherapy in NSCLC

Ulas D. Bayraktar, MD
2023-01-10
Non-Small Cell Lung Cancer

New Indication: Adjuvant Pembrolizumab in NSCLC

Ulas D. Bayraktar, MD
2022-11-26
Non-Small Cell Lung Cancer

New Drug: Selpercatinib in RET-Fusion Positive NSCLC

Ulas D. Bayraktar, MD
2022-11-26
Non-Small Cell Lung Cancer

New Indication: Neoadjuvant Nivolumab for NSCLC

Ulas D. Bayraktar, MD
2022-09-20
Non-Small Cell Lung Cancer

New Indication: Trastuzumab Deruxtecan for her2-Mutant NSCLC

Ulas D. Bayraktar, MD
2022-03-16

Posts pagination

1 2 3
  • Library
  • F.A.Q.
  • Contact Us

Privacy Policy

Altai, Inc (USA)

30 N Gould St, Ste 6801

Sheridan, WY, 82801, USA

Phone: +1 (978) 393 0042

Altay Tıp Sağlık Yazılım AŞ (Türkiye)

Mutlukent Mah Manuk Bey Sk No: 4

Çankaya, Ankara, 06800, Türkiye

Phone: +90 (312) 911 5735

Our Terms & Privacy Policy

Copyright - 2024 - Altai Inc - All rights reserved

Back to top Drag
  • Library
  • Articles
  • Patient Education
  • F.A.Q.
  • Contact Us

jghghjghjghhgj